Search results for " Pituitary"

showing 10 items of 51 documents

Die Diurese der Maus nach oraler Gabe von Wasser oder NaCl-L�sungen und ihre Beeinflussung durch Hypophysenhinterlappenhormone

1959

Pharmacologymedicine.medical_specialtyChemistryNacl solutionsPharmacology toxicologyDiuresisGeneral Medicinemedicine.anatomical_structureEndocrinologyPosterior pituitaryOral administrationInternal medicinemedicineHormoneNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

Adherence to growth hormone (GH) therapy in naïve to treatment GH-deficient children: data of the Italian Cohort from the Easypod Connect Observation…

2019

Background: With the use of non-objective measurement, adherence to growth hormone (GH) therapy has been reported suboptimal in a large proportion of patients, and poor adherence has been shown to affect short-term growth response in patients receiving GH treatment. Objective: The Easypod™ electronic device allows objective measurement of adherence. In this study, we report 3-year prospective adherence data of the Italian cohort of naïve GH deficient (GHD) children extrapolated from the Easypod Connect Observational Study (ECOS) database. Patients and methods: Seventy-three GHD children naïve to GH treatment were included in the analysis. 22 Italian centers participated in the study. Result…

MalePediatricsDatabases FactualChildren; ECOS; GHD; Growth hormone; Short statureEndocrinology Diabetes and MetabolismChildren; ECOS; GHD; Growth hormone; Short stature;Children; ECOS; GHD; Growth hormone; Short stature; Adolescent; Child; Cohort Studies; Databases Factual; Dwarfism Pituitary; Female; Growth Disorders; Human Growth Hormone; Humans; Italy; Male; Medication Adherence; Telemedicine; Medical Records Systems Computerized; Wearable Electronic DevicesGrowth hormoneCohort Studies0302 clinical medicineEndocrinologyChildChildrenGrowth DisordersHuman Growth HormoneChildren ECOS GHD Growth hormone Short statureObjective measurementSettore MED/38TelemedicineItaly030220 oncology & carcinogenesisCohortFemaleOriginal ArticleMedical Records Systemsmedicine.symptomCohort studymedicine.medical_specialtyAdolescentMedical Records Systems ComputerizedDwarfism030209 endocrinology & metabolismShort statureMedication AdherenceDatabasesWearable Electronic Devices03 medical and health sciencesmedicineHumansIn patientDwarfism PituitaryGrowth hormoneFactualbusiness.industryComputerizedShort staturePituitaryGh treatmentECOSObservational studybusinessGHDJournal of Endocrinological Investigation
researchProduct

Early Lung Function Abnormalities in Acromegaly.

2014

BACKGROUND: Acromegaly is an insidious disorder caused by a pituitary growth hormone (GH)-secreting adenoma resulting in high circulating levels of GH and insulin-like growth factor I (IGF-I). Respiratory disorders are common complications in acromegaly, and can severely impact on quality of life, eventually affecting mortality. OBJECTIVES: The present study aimed to explore structural and functional lung alterations of acromegalic subjects. METHODS: We enrolled 10 consecutive patients (M/F: 5/5) affected by acromegaly. In all patients, magnetic resonance imaging (MRI) revealed the presence of pituitary tumor. All patients underwent clinical, lung functional, biological, and radiological as…

AdultLung DiseasesMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTime FactorsAdenomaVital CapacitySettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyspirometry dyspnea acromegalySettore MED/13 - EndocrinologiaPredictive Value of TestsDLCOForced Expiratory VolumeDiffusing capacityInternal medicineAcromegalymedicineHumansLung volumesRespiratory systemLungAgedLungbusiness.industryPituitary tumorsMiddle Agedrespiratory systemmedicine.diseaseMagnetic Resonance Imagingrespiratory tract diseasesRadiographyEarly Diagnosismedicine.anatomical_structureCase-Control StudiesPulmonary Diffusing CapacityFemaleGrowth Hormone-Secreting Pituitary AdenomaLung Volume Measurementsbusiness
researchProduct

The oxytocin receptor system: structure, function, and regulation.

2001

The neurohypophysial peptide oxytocin (OT) and OT-like hormones facilitate reproduction in all vertebrates at several levels. The major site of OT gene expression is the magnocellular neurons of the hypothalamic paraventricular and supraoptic nuclei. In response to a variety of stimuli such as suckling, parturition, or certain kinds of stress, the processed OT peptide is released from the posterior pituitary into the systemic circulation. Such stimuli also lead to an intranuclear release of OT. Moreover, oxytocinergic neurons display widespread projections throughout the central nervous system. However, OT is also synthesized in peripheral tissues, e.g., uterus, placenta, amnion, corpus lut…

Malemedicine.medical_specialtyPhysiologyOxytocin receptor bindingCentral nervous systemMolecular Sequence DataBiologyOxytocinPosterior pituitaryPhysiology (medical)Internal medicineNeoplasmsSequence Homology Nucleic AcidmedicineAnimalsHumansAmino Acid SequenceReceptorMolecular BiologyBehaviorBase SequenceBehavior AnimalSequence Homology Amino AcidGeneral MedicineOxytocin receptorBiological EvolutionEndocrinologymedicine.anatomical_structureOxytocinReceptors OxytocinMagnocellular cellFemaleSignal transductionSequence Alignmentmedicine.drugSignal TransductionPhysiological reviews
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

Developmental Changes and Daily Rhythm in Melatonin-Induced Inhibition of 3′,5′-Cyclic AMP Accumulation in the Rat Pituitary

1990

Melatonin's transduction mechanisms were investigated using in vitro cultured anterior hemipituitaries. Melatonin inhibited cAMP and 3',5'-cyclic GMP accumulation in neonatal rat anterior pituitary stimulated with LHRH. Maximal inhibitory effect was reached within 25 min and persisted for at least 20 min. Inhibition of cAMP accumulation is specific for melatonin because its analogs N-acetylserotonin and 5-methoxytryptamine are 1000 times less potent. Melatonin effect is age- and time-dependent. Marked inhibition was observed in 5-, 10-, and 14-day-old rats but not in 29-day-old ones. Melatonin was significantly more potent when applied at the end of the light period as compared with the fir…

Agingendocrine systemmedicine.medical_specialtyPituitary glandTime FactorsGonadotropin-releasing hormoneIn Vitro TechniquesBiologyGonadotropin-Releasing HormoneMelatoninEndocrinologyAnterior pituitaryInternal medicineCyclic AMPmedicineAnimalsCircadian rhythmCyclic GMPMelatoninDose-Response Relationship DrugRats Inbred StrainsCircadian RhythmRatsDose–response relationshipEndocrinologymedicine.anatomical_structurePituitary GlandSecond messenger systemhormones hormone substitutes and hormone antagonistsEndocrine glandmedicine.drugEndocrinology
researchProduct

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease

2019

Abstract Background: Clinical trials have shown that subcutaneous (sc) pasireotide effectively decreases urinary free cortisol (UFC), improves signs/symptoms and has a favorable safety profile in patients with Cushing’s disease (CD). We describe interim long-term safety and efficacy results of an ongoing multicenter observational study of pasireotide sc in real-world clinical practice for CD (NCT02310269). Methods: This study aims to enroll 100-200 adults with CD for whom surgery has failed or is not an option. Eligible patients could have started pasireotide before (prior use) or at (new use) study entry. Primary endpoint: incidence of pasireotide-related adverse events (AEs) and serious A…

Pediatricsmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismLong term resultsCushing's diseasemedicine.diseasePasireotidechemistry.chemical_compoundNeuroendocrinology and PituitarychemistryNon interventionalmedicineObservational studybusinessJournal of the Endocrine Society
researchProduct

Zum Einfluss von Angiotensin II auf die Nebennierenrinde unter chemischer adrenostase mit SU 4885 (Metopiron)

1964

The inhibition of 11-β-hydroxylase in the adrenal cortex with SU 4885 (metopiron) increases the ACTH-secretion. Val5-angiotensin II blocks the reaction of the anterior pituitary gland similarly as does dexamethasone. Mode and intensity of this action of angiotensin II, and the influence on rats treated as described, are studied.

Pharmacologymedicine.medical_specialtyChemistryAdrenal cortexCell BiologyAngiotensin IICellular and Molecular Neurosciencemedicine.anatomical_structureEndocrinologyAnterior pituitaryInternal medicinemedicineMolecular MedicineMolecular BiologyDexamethasonemedicine.drugExperientia
researchProduct

Increased LH and FSH release from the anterior pituitary of ovariectomized rat, in vivo, by copper-, nickel-, and zinc-LHRH complexes.

1992

Abstract The effect of Cu 2+ , Ni 2+ , Zn 2+ and their complexes with LHRH on the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) was estimated in in vivo experiments with the use of the method proposed by Ramirez and McCann. Ovariectomized, estradiol, and progesterone pretreated rats were injected intraveneously either with LHRH alone, a metal ion alone, a mixture of metal and hormone, or a metal-LHRH complex. A metal alone or a mixture of it with LHRH did not affect gonadotropin release at all or no more than LHRH alone. However, the complex of Cu 2+ with LHRH brought about a high release of LH and even higher release of FSH. This indicates that copper complex i…

endocrine systemmedicine.medical_specialtymedicine.drug_classOvariectomyPeptide hormoneBiochemistryInorganic ChemistryGonadotropin-Releasing HormoneFollicle-stimulating hormoneAnterior pituitaryIn vivoNickelPituitary Gland AnteriorInternal medicinemedicineAnimalsProgesteroneEstradiolChemistryRats Inbred StrainsLuteinizing HormoneRatsZincmedicine.anatomical_structureEndocrinologyMetalsOvariectomized ratFemaleGonadotropinFollicle Stimulating HormoneLuteinizing hormonehormones hormone substitutes and hormone antagonistsCopperHormoneJournal of inorganic biochemistry
researchProduct